



National Center  
for Advancing  
Translational Sciences

**Joint Meeting of the  
National Center for Advancing Translational Sciences Advisory Council  
(11<sup>th</sup> Meeting)  
and  
Cures Acceleration Network Review Board (14<sup>th</sup> Meeting)**

**January 14, 2016**

8:30 a.m. – 4:30 p.m.

Building 31C, 6<sup>th</sup> Floor, Conference Room 10  
Bethesda, Maryland 20892

**Future Advisory Council & CAN Review Board Joint Meetings**

**2016**

May 12  
September 15

**2017**

January 12  
May 4  
September 7

**Future CAN Review Board (only) Meetings (by phone)**

**2016**

December 9

**2017**

December 15

**Agenda – OPEN SESSION**

Open Session of the meeting will be webcast. To view, please go to: <http://videocast.nih.gov>

**8:30 – 8:45 a.m.**

**Call to Order, Open Session**

Christopher P. Austin, M.D., Director, NCATS; Chairperson – Advisory Council

Freda C. Lewis-Hall, M.D., Chief Medical Officer, Pfizer; Chairperson – CAN Review Board

<b>8:45 – 9:00 a.m.</b>	<p><b>Approval of Minutes from September 2015 Joint Meeting</b></p> <p><b>Confirmation of Dates for Future NCATS Advisory Council/CAN Review Board Meetings</b>  Anna L. Ramsey-Ewing, Ph.D., Executive Secretary, NCATS Advisory Council and CAN Review Board; Director, Office of Grants Management and Scientific Review, NCATS</p> <p><b>Introduction of New Staff</b></p>
<b>9:00 – 10:00 a.m.</b>	<p><b>NCATS Director’s Report</b>  Christopher P. Austin, M.D., Director, NCATS</p> <p>Discussion</p>
<b>10:00 – 10:30 a.m.</b>	<b>BREAK</b>
<b>10:30 – 10:45 a.m.</b>	<p><b>CAN Review Board Update</b>  Freda C. Lewis-Hall, M.D., Chief Medical Officer, Pfizer; Chairperson – CAN Review Board</p>
<b>10:45 – 11:15 a.m.</b>	<p><b>NCATS Strategic Planning Update</b>  Dorit Zuk, Ph.D., Director, Office of Policy, Communications and Strategic Alliances, NCATS</p> <p>Discussion</p>
<b>11:15 a.m. – Noon</b>	<p><b>Clearance of Concepts</b></p> <ul style="list-style-type: none"> <li>• <b><i>Clinical and Translational Science Data Metrics Coordinating Center</i></b> – Petra Kaufmann, M.D., M.Sc., Director, Office of Rare Diseases Research and the Division of Clinical Innovation, NCATS</li> <li>• <b><i>Collaborative Innovation Pilot Projects for the CTSA Program</i></b> – Petra Kaufmann, M.D., M.Sc., Director, Office of Rare Diseases Research and the Division of Clinical Innovation, NCATS</li> </ul>
<b>Noon – 1:00 p.m.</b>	<b>LUNCH</b>

1:00 – 1:45 p.m.

**NCATS Partnerships with NIH Common Fund**

- **Overview** – Danilo A. Tagle, Ph.D., Associate Director for Special Initiatives, NCATS
- **Extracellular RNA (ExRNA) Communication Program** – Danilo A. Tagle, Ph.D., Associate Director for Special Initiatives, NCATS
- **Undiagnosed Diseases Network (UDN) Program** – Carson R. Loomis, Ph.D., Senior Advisor to the Director, NCATS; and David J. Eckstein, Ph.D., Senior Health Scientist Administrator, Office of Rare Diseases Research, NCATS

1:45 – 2:45 p.m.

**CTSA Program Updates**

Petra Kaufmann, M.D., M.Sc., Director, Office of Rare Diseases Research and the Division of Clinical Innovation, NCATS

Discussion

2:45 p.m.

**Adjourn, Open Session**

3:00 – 4:30 p.m.

**Closed Session**

This portion of the meeting is closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S. Code and Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).

**Review of Conflict of Interest, Confidentiality and Council Procedures**

Anna L. Ramsey-Ewing, Ph.D., Executive Secretary, NCATS Advisory Council and CAN Review Board; Director, Office of Grants Management and Scientific Review, NCATS

**Council Consideration of Pending Applications**

Anna L. Ramsey-Ewing, Ph.D., Executive Secretary, NCATS Advisory Council and CAN Review Board; Director, Office of Grants Management and Scientific Review, NCATS

4:30 p.m.

**Adjourn, Closed Session**